litlas
Log inCreate account

Daniel H. Palmer

Active 2001–2025

87
Papers
27,969
Citations
57
h-index
84
i10-index

Citations

Citations per year for Daniel H. Palmer1939: 2 citations1993: 1 citations2002: 3 citations2003: 3 citations2004: 8 citations2005: 4 citations2006: 3 citations2007: 14 citations2008: 9 citations2009: 10 citations2010: 21 citations2011: 40 citations2012: 68 citations2013: 64 citations2014: 77 citations2015: 120 citations2016: 130 citations2017: 177 citations2018: 247 citations2019: 1,126 citations2020: 1,624 citations2021: 1,665 citations2022: 1,289 citations2023: 937 citations2024: 1,497 citations2025: 641 citations2026: 10 citations1940–1992: no citations, so these years are not shown1994–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,473 citing papers, 19.2% of this breakdownChina: 2,363 citing papers, 18.4% of this breakdownJapan: 834 citing papers, 6.5% of this breakdownGermany: 802 citing papers, 6.2% of this breakdownItaly: 793 citing papers, 6.2% of this breakdownUnited Kingdom: 765 citing papers, 5.9% of this breakdownFrance: 473 citing papers, 3.7% of this breakdownSpain: 395 citing papers, 3.1% of this breakdownSouth Korea: 360 citing papers, 2.8% of this breakdownCanada: 343 citing papers, 2.7% of this breakdownNetherlands: 294 citing papers, 2.3% of this breakdownTaiwan: 251 citing papers, 2% of this breakdown
0%19.2%Other 21%

Institutions

Fields

  • Medicine77%
  • Biochemistry, Genetics and Molecular Biology14.4%
  • Immunology and Microbiology5.3%
  • Engineering1%
  • Materials Science0.8%
  • Neuroscience0.4%
  • Other1.1%

Topics

  • Pancreatic and Hepatic Oncology Research9.8%
  • Cholangiocarcinoma and Gallbladder Cancer Studies9.5%
  • Hepatocellular Carcinoma Treatment and Prognosis9.3%
  • Cancer Immunotherapy and Biomarkers5.2%
  • Gallbladder and Bile Duct Disorders3.6%
  • Liver Disease Diagnosis and Treatment2.6%
  • Other60%

Coauthors

All papers

Open in search
  1. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

    Authors: Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita - The Lancet Oncology 2018 cited by 2,536

  2. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

    Authors: Juan W. Valle, Harpreet Wasan, Daniel H. Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Timothy Iveson, S. Hughes, Stephen P. Pereira, Sy Ha, John Bridgewater - New England Journal of Medicine 2010 cited by 4,404

  3. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

    Authors: Philip J. Johnson, Sarah Berhane, Chiaki Kagebayashi, Shinji Satomura, Mabel Teng, Helen L. Reeves, James O’Beirne, Richard Fox, Anna Skowrońska, Daniel H. Palmer, Winnie Yeo, Frankie Mo, Paul B.S. Lai, Mercedes Iñarrairaegui, Stephen L. Chan, Bruno Sangro, Rebecca A. Miksad, Toshifumi Tada, Takashi Kumada, Hidenori Toyoda - Journal of Clinical Oncology 2014 cited by 2,755

  4. Therapeutic developments in pancreatic cancer: current and future perspectives

    Authors: John P. Neoptolemos, Jörg Kleeff, Patrick Michl, Eithne Costello, William Greenhalf, Daniel H. Palmer - Nature Reviews Gastroenterology & Hepatology 2018 cited by 1,234

  5. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

    Authors: John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh, Eftychia Eirini Psarelli, Juan W. Valle, Christopher Halloran, Olusola Olusesan Faluyi, Derek O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R. Izbicki, Gary Middleton, Sebastian Cummins, Paul J. Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W. Büchler - The Lancet 2017 cited by 1,928

  6. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

    Authors: John N Primrose, Richard Fox, Daniel H. Palmer, Hassan Malik, Rajendra Prasad, Darius Mirza, Alan Anthony, Pippa Corrie, Stephen Falk, Meg Finch-Jones, Harpreet Wasan, Paul J. Ross, Lucy Wall, Jonathan Wadsley, JEFF EVANS, Deborah Stocken, Raaj Praseedom, Yuk Ting, Brian R Davidson, John P. Neoptolemos, Timothy Iveson, James Raftery, Shihua Zhu, David Cunningham, O. James Garden, Clive Stubbs, Juan W. Valle, John Bridgewater, John Primrose, RP Fox, Helen Morement, Oscar S.H. Chan, C. Rees, Ma Yt, Tamas Hickish, Stephen Falk, Meg Finch-Jones, Ian Pope, Pippa Corrie, Tom Crosby, S. Sothi, K Sharkland, Douglas Adamson, Lucy Wall, JEFF EVANS, John Dent, U. Hombaiah, Chinenye Iwuji, Alan Anthoney, John Bridgewater, David Cunningham, Roopinder Gillmore, Paul J. Ross, S. Slater, Harpreet Wasan, Jill Waters, Juan W. Valle, Daniel H. Palmer, Hafiz Malik, John P. Neoptolemos, Olusola Olusesan Faluyi, Kate Sumpter, U. Dernedde, S Maduhusudan, G. Cogill, Caroline Archer, Timothy Iveson, Jonathan Wadsley, Suzanne Darby, Mike Peterson, AA Mukhtar, JG Thorpe, Adrian C Bateman, D. Tsang, S. Cummins, L. Nolan, Éric Beaumont, Rajendra Prasad, D. Mirza, Deborah Stocken, Raaj Praseedom, Brian R Davidson, James Raftery, Shihua Zhu, James Garden, C Stubbs, Fareeda Y. Coxon - The Lancet Oncology 2019 cited by 1,228

  7. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

    Authors: Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, Paul J. Ross, Yuk Ting, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Timothy Iveson, Justin S. Waters, Claire Hobbs, Safia Barber, W. David J. Ryder, John Ramage, Linda Davies, John Bridgewater, Juan W. Valle - The Lancet Oncology 2021 cited by 749

  8. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

    Authors: Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky, Andrew Dean, Yan‐Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, J.F. Blanc, Richard Hubner, Chang‐Fang Chiu, Gilberto Schwartsmann, Jens T. Siveke, Fadi Braiteh, Victor Moyo, Bruce Belanger, Navreet Dhindsa, Eliel Bayever, Daniel D. Von Hoff, Li‐Tzong Chen, Clarence S. Adoo, T Anderson, Jamil Asselah, Alan A. Azambuja, Carolyn Bampton, Carlos H. Barrios, Tanios Bekaii‐Saab, Bohuslav Melichar, David Chang, Jen‐Shi Chen, Yeu‐Chin Chen, Hye Jin Choi, Ik Joo Chung, Vincent Chung, Tibor Csőszi, Antonio Cubillo, Linda C. DeMarco, Maike de Wit, Tomislav Dragovich, W. Jeff Edenfield, Luis Fein, Fábio Franke, Martin Fuchs, Vega Gonzales-Cruz, Alberto Gozza, Rivera Herrero Fernando, Rosario Vincenzo Iaffaioli, Jitka Jakesova, Zsuzsanna Kahán, Misagh Karimi, Jun Suk Kim, Ernesto Korbenfeld, István Láng, Fa-Chyi Lee, Kuan‐Der Lee, Lara Lipton, Wen Wee, László Mangel, Raul Mena, Daniel H. Palmer, Shubham Pant, Joon Oh Park, Paolo Piacentini, Uwe Pelzer, Javier Gállego, Cooray Prasad, Kun‐Ming Rau, Jean‐Luc Raoul, Donald Richards, Paul J. Ross, Luís Alberto Schlittler, Martin Šmakal, V. Stahalova, Cora N. Sternberg, Thomas Seufferlein, Niall C. Tebbutt, J. Vinholes, Raymond Wadlow, Milkos Wenczl, Mark Wong - The Lancet 2015 cited by 1,200

  9. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

    Authors: Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi, Richard Jackson, Christopher Halloran, Charlotte Rawcliffe, Rajaram Sripadam, Somnath Mukherjee, Zahir Soonawalla, Jonathan Wadsley, Ahmed Al-Mukhtar, Euan J. Dickson, Janet Graham, Long R. Jiao, Harpreet Wasan, Iain S. Tait, Andreas Prachalias, Paul J. Ross, Juan W. Valle, Derek O’Reilly, Bilal Al‐Sarireh, Sarah Gwynne, Irfan Ahmed, Kate Connolly, Kein-Long Yim, David Cunningham, Thomas Armstrong, Caroline Archer, Keith Roberts, Yuk Ting, Christoph Springfeld, Christine Tjaden, Thilo Hackert, Markus W. Büchler, John P. Neoptolemos - ˜The œLancet. Gastroenterology & hepatology 2022 cited by 325

  10. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis

    Authors: Sebastian R. Nielsen, Valeria Quaranta, Andrea Linford, Perpetua U. Emeagi, Carolyn Rainer, Almudena Santos, Lucy Ireland, Takao Sakai, Keiko Sakai, Yong-Sam Kim, Dannielle D. Engle, Fiona Campbell, Daniel H. Palmer, Jeong Heon Ko, David A. Tuveson, Emilio Hirsch, Ainhoa Mielgo, Michael C. Schmid - Nature Cell Biology 2016 cited by 434

  11. Single-cell analyses of aging, inflammation and senescence

    Authors: Bora Uyar, Daniel H. Palmer, Axel Kowald, Hugo Murua Escobar, Israel Barrantes, Steffen Möller, Altuna Akalin, Georg Fuellen - Ageing Research Reviews 2020 cited by 218

  12. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

    Authors: Debashis Sarker, Ruth Plummer, Tim Meyer, Mikael H. Sodergren, Bristi Basu, Cheng Ean Chee, Kai‐Wen Huang, Daniel H. Palmer, Yuk Ting, T.R. Jeff Evans, Duncan Spalding, Madhava Pai, Rohini Sharma, David J. Pinato, James Spicer, Sarah Hunter, Vineet Kwatra, Joanna P. Nicholls, D Michael Collin, Robert Nutbrown, Helen Glenny, Sonia Fairbairn, Vikash Reebye, Jon Voutila, Stephanie Dorman, Pinelopi Andrikakou, Peter Lloyd, Steve Felstead, Jenni Vasara, Robert Habib, Chris B. Wood, Pål Sætrom, Hans E. Huber, David C. Blakey, John J. Rossi, Nagy Habib - Clinical Cancer Research 2020 cited by 175

  13. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis

    Authors: Gaia Bellomo, Carolyn Rainer, Valeria Quaranta, Yuliana Astuti, Meirion Raymant, Elzbieta Boyd, Ruth Stafferton, Fiona Campbell, Paula Ghaneh, Christopher Halloran, Dean E. Hammond, Jennifer P. Morton, Daniel H. Palmer, Dale Vimalachandran, Robert Jones, Ainhoa Mielgo, Michael C. Schmid - Gut 2022 cited by 110

  14. Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

    Authors: John P. Neoptolemos, Deborah Stocken, Claudio Bassi, Paula Ghaneh, David Cunningham, David Goldstein, Robert Padbury, Malcolm J. Moore, Steven Gallinger, C. Mariette, Moritz N. Wente, Jakob R. Izbicki, Helmut Friess, Markus M. Lerch, Christos Dervenis, Attila Oláh, Giovanni Butturini, Ryuichiro Doi, Pehr Lind, David B. Smith, Juan W. Valle, Daniel H. Palmer, John Buckels, Joyce Thompson, Colin J. McKay, Charlotte Rawcliffe, Markus W. Büchler, for the European Study Group for Pancreatic Cancer - JAMA 2010 cited by 1,387

  15. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

    Authors: Tim Meyer, Richard Fox, Yuk Ting, Paul J. Ross, Martin W. James, Richard Sturgess, Clive Stubbs, Deborah Stocken, Lucy Wall, Anthony Watkinson, Nigel Hacking, T.R. Jeffry Evans, Peter L. Collins, Richard Hubner, David Cunningham, John Primrose, Philip J. Johnson, Daniel H. Palmer - ˜The œLancet. Gastroenterology & hepatology 2017 cited by 497

  16. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

    Authors: Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong‐Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung‐Hwan Yoon, Sunil Sharma, Zhong-Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia-Jui Yen, Jean‐François Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon‐Koo Kang - Cancer Discovery 2019 cited by 250

  17. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study

    Authors: John Bridgewater, Peter Fletcher, Daniel H. Palmer, Hassan Z. Malik, Raj Prasad, Darius Mirza, Alan Anthony, Pippa Corrie, Stephen Falk, Meg Finch-Jones, Harpreet Wasan, Paul Ross, Lucy Wall, Jonathan Wadsley, Thomas R. Evans, Deborah Stocken, Clive Stubbs, Raaj Praseedom, Yuk Ting Ma, Brian Davidson, John Neoptolemos, Tim Iveson, David Cunningham, O. James Garden, Juan W. Valle, John Primrose, on behalf of the BILCAP study group - Journal of Clinical Oncology 2022 cited by 189

  18. The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers

    Authors: Philip J. Johnson, Sarah Pirrie, Trevor F. Cox, Sarah Berhane, Mabel Teng, Daniel H. Palmer, Janet Morse, Diana Hull, Gillian Patman, Chiaki Kagebayashi, Syed A. Hussain, Janine Graham, Helen L. Reeves, Shinji Satomura - Cancer Epidemiology Biomarkers & Prevention 2013 cited by 335

  19. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

    Authors: Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Thomas Yau, Ellen B. Gurary, Abby B. Siegel, Anran Wang, Ann‐Lii Cheng, Andrew X. Zhu - European Journal of Cancer 2022 cited by 129

  20. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma

    Authors: Robert Jones, Eftychia‐Eirini Psarelli, Richard Jackson, Paula Ghaneh, Christopher Halloran, Daniel H. Palmer, Fiona Campbell, Juan W. Valle, Olusola Olusesan Faluyi, Derek O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R. Izbicki, Gary Middleton, Sebastian Cummins, Paul J. Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Markus M. Lerch, Julia Mayerle, Christine Tjaden, Oliver Strobel, Thilo Hackert, Markus W. Büchler, John P. Neoptolemos, for the European Study Group for Pancreatic Cancer - JAMA Surgery 2019 cited by 273

  21. A human tissue‐specific transcriptomic analysis reveals a complex relationship between aging, cancer, and cellular senescence

    Authors: Kasit Chatsirisupachai, Daniel H. Palmer, Susana Isabel Ferreira, João Pedro de Magalhães - Aging Cell 2019 cited by 158

  22. Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis

    Authors: Yuliana Astuti, Meirion Raymant, Valeria Quaranta, Kim Clarke, Maidinaimu Abudula, Olivia Smith, Gaia Bellomo, Vatshala Chandran-Gorner, Craig Nourse, Christopher Halloran, Paula Ghaneh, Daniel H. Palmer, Robert Jones, Fiona Campbell, Jeffrey W. Pollard, Jennifer P. Morton, Ainhoa Mielgo, Michael C. Schmid - Nature Cancer 2024 cited by 88

  23. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer

    Authors: Ayumi Hashimoto, Debashis Sarker, Vikash Reebye, Sheba Jarvis, Mikael H. Sodergren, Andrew V. Kossenkov, Emilio Sanseviero, Nina Raulf, Jenni Vasara, Pinelopi Andrikakou, Tim Meyer, Kai‐Wen Huang, Ruth Plummer, Cheng Ean Chee, Duncan Spalding, Madhava Pai, Shahid A. Khan, David J. Pinato, Rohini Sharma, Bristi Basu, Daniel H. Palmer, Yuk Ting, JEFF EVANS, Robert Habib, Աննա Մարտիրոսյան, Naouel Elasri, Adeline Reynaud, John J. Rossi, Mark Cobbold, Nagy Habib, Dmitry I. Gabrilovich - Clinical Cancer Research 2021 cited by 91

  24. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

    Authors: Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stal, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stephane Cattan, Masatoshi Kudo, Ann-Lii Cheng, Sadahisa Ogasawara, Bruno Daniele, Stephen L. Chan, Jennifer J. Knox, Shukui Qin, Abby B. Siegel, Michael Chisamore, Ken Hatogai, Anran Wang, Richard S. Finn, Andrew X. Zhu - Clinical Cancer Research 2022 cited by 84